The renin-angiotensin system in the eye

K. Ströder, T. Unger, Ulrike Muscha Steckelings

Publikation: Bidrag til bog/antologi/rapport/konference-proceedingBidrag til bog/antologiForskningpeer review

Resumé

The renin-angiotensin system (RAS) is a phylogenetically old hormonal system which serves to control blood pressure, volume and electrolyte homeostasis. Apart from these main systemic effects, the RAS - when overactivated - is further involved in a broad spectrum of cardiovascular diseases ranging from arterial hypertension, atherosclerosis, and cardiac hypertrophy to diabetic or autoimmune nephropathy. Experimental data have provided strong evidence that a local RAS is also expressed in the eye, in particular in the retina and in retinal vessels, and that this ocular RAS is overactivated in diabetes, thus contributing to the pathogenesis of diabetic retinopathy. In this context, the ocular RAS promotes retinal damage by (a) direct effects of angiotensin II via the angiotensin AT1-receptor, and (b) bidirectional interaction with the 'classical' hyperglycemia-induced pathobiochemical pathways (generation of advanced glycation end products, increased polyol pathway flux, activation of protein kinase C, increased hexosamine pathway flux, overproduction of superoxide). The involvement of the RAS in the pathomechanisms underlying diabetic retinopathy suggests pharmacological RAS inhibition as a therapeutic option in this disease. Preclinical data in fact indicate that angiotensin-converting enzyme inhibitors and AT1 receptor blockers are able to confer retinoprotection, and this was further supported by recent clinical trials (EURODIAB, DIRECT).
OriginalsprogEngelsk
TitelFrontiers in Diabetes
Antal sider16
Vol/bind20
Publikationsdato1. jan. 2010
Sider142-157
DOI
StatusUdgivet - 1. jan. 2010
Udgivet eksterntJa

Fingeraftryk

Renin-Angiotensin System
Diabetic Retinopathy
Angiotensin Type 1 Receptor
Advanced Glycosylation End Products
Hyperglycemia
Electrolytes
Retina
Homeostasis
Clinical Trials

Citer dette

Ströder, K., Unger, T., & Steckelings, U. M. (2010). The renin-angiotensin system in the eye. I Frontiers in Diabetes (Bind 20, s. 142-157) https://doi.org/10.1159/000262667
Ströder, K. ; Unger, T. ; Steckelings, Ulrike Muscha. / The renin-angiotensin system in the eye. Frontiers in Diabetes. Bind 20 2010. s. 142-157
@inbook{ae9cc291cb4647b0a91abe2f6f13fb8d,
title = "The renin-angiotensin system in the eye",
abstract = "The renin-angiotensin system (RAS) is a phylogenetically old hormonal system which serves to control blood pressure, volume and electrolyte homeostasis. Apart from these main systemic effects, the RAS - when overactivated - is further involved in a broad spectrum of cardiovascular diseases ranging from arterial hypertension, atherosclerosis, and cardiac hypertrophy to diabetic or autoimmune nephropathy. Experimental data have provided strong evidence that a local RAS is also expressed in the eye, in particular in the retina and in retinal vessels, and that this ocular RAS is overactivated in diabetes, thus contributing to the pathogenesis of diabetic retinopathy. In this context, the ocular RAS promotes retinal damage by (a) direct effects of angiotensin II via the angiotensin AT1-receptor, and (b) bidirectional interaction with the 'classical' hyperglycemia-induced pathobiochemical pathways (generation of advanced glycation end products, increased polyol pathway flux, activation of protein kinase C, increased hexosamine pathway flux, overproduction of superoxide). The involvement of the RAS in the pathomechanisms underlying diabetic retinopathy suggests pharmacological RAS inhibition as a therapeutic option in this disease. Preclinical data in fact indicate that angiotensin-converting enzyme inhibitors and AT1 receptor blockers are able to confer retinoprotection, and this was further supported by recent clinical trials (EURODIAB, DIRECT).",
author = "K. Str{\"o}der and T. Unger and Steckelings, {Ulrike Muscha}",
year = "2010",
month = "1",
day = "1",
doi = "10.1159/000262667",
language = "English",
volume = "20",
pages = "142--157",
booktitle = "Frontiers in Diabetes",

}

Ströder, K, Unger, T & Steckelings, UM 2010, The renin-angiotensin system in the eye. i Frontiers in Diabetes. bind 20, s. 142-157. https://doi.org/10.1159/000262667

The renin-angiotensin system in the eye. / Ströder, K.; Unger, T.; Steckelings, Ulrike Muscha.

Frontiers in Diabetes. Bind 20 2010. s. 142-157.

Publikation: Bidrag til bog/antologi/rapport/konference-proceedingBidrag til bog/antologiForskningpeer review

TY - CHAP

T1 - The renin-angiotensin system in the eye

AU - Ströder, K.

AU - Unger, T.

AU - Steckelings, Ulrike Muscha

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The renin-angiotensin system (RAS) is a phylogenetically old hormonal system which serves to control blood pressure, volume and electrolyte homeostasis. Apart from these main systemic effects, the RAS - when overactivated - is further involved in a broad spectrum of cardiovascular diseases ranging from arterial hypertension, atherosclerosis, and cardiac hypertrophy to diabetic or autoimmune nephropathy. Experimental data have provided strong evidence that a local RAS is also expressed in the eye, in particular in the retina and in retinal vessels, and that this ocular RAS is overactivated in diabetes, thus contributing to the pathogenesis of diabetic retinopathy. In this context, the ocular RAS promotes retinal damage by (a) direct effects of angiotensin II via the angiotensin AT1-receptor, and (b) bidirectional interaction with the 'classical' hyperglycemia-induced pathobiochemical pathways (generation of advanced glycation end products, increased polyol pathway flux, activation of protein kinase C, increased hexosamine pathway flux, overproduction of superoxide). The involvement of the RAS in the pathomechanisms underlying diabetic retinopathy suggests pharmacological RAS inhibition as a therapeutic option in this disease. Preclinical data in fact indicate that angiotensin-converting enzyme inhibitors and AT1 receptor blockers are able to confer retinoprotection, and this was further supported by recent clinical trials (EURODIAB, DIRECT).

AB - The renin-angiotensin system (RAS) is a phylogenetically old hormonal system which serves to control blood pressure, volume and electrolyte homeostasis. Apart from these main systemic effects, the RAS - when overactivated - is further involved in a broad spectrum of cardiovascular diseases ranging from arterial hypertension, atherosclerosis, and cardiac hypertrophy to diabetic or autoimmune nephropathy. Experimental data have provided strong evidence that a local RAS is also expressed in the eye, in particular in the retina and in retinal vessels, and that this ocular RAS is overactivated in diabetes, thus contributing to the pathogenesis of diabetic retinopathy. In this context, the ocular RAS promotes retinal damage by (a) direct effects of angiotensin II via the angiotensin AT1-receptor, and (b) bidirectional interaction with the 'classical' hyperglycemia-induced pathobiochemical pathways (generation of advanced glycation end products, increased polyol pathway flux, activation of protein kinase C, increased hexosamine pathway flux, overproduction of superoxide). The involvement of the RAS in the pathomechanisms underlying diabetic retinopathy suggests pharmacological RAS inhibition as a therapeutic option in this disease. Preclinical data in fact indicate that angiotensin-converting enzyme inhibitors and AT1 receptor blockers are able to confer retinoprotection, and this was further supported by recent clinical trials (EURODIAB, DIRECT).

UR - http://www.scopus.com/inward/record.url?scp=77649111249&partnerID=8YFLogxK

U2 - 10.1159/000262667

DO - 10.1159/000262667

M3 - Book chapter

VL - 20

SP - 142

EP - 157

BT - Frontiers in Diabetes

ER -

Ströder K, Unger T, Steckelings UM. The renin-angiotensin system in the eye. I Frontiers in Diabetes. Bind 20. 2010. s. 142-157 https://doi.org/10.1159/000262667